Hepatitis C FDA-Approved
Combination Therapy

  Pegasys + Copegus (peginterferon alfa-2a + ribavirin)
  PegIntron + Rebetol (peginterferon alfa-2b + ribavirin)
  Roferon A + Ribavirin (Standard interferon alfa-2a + ribavirin)
  Intron A + Rebetol (Standard Interferon alfa-2b + ribavirin)

Articles on Pegasys + Copegus

Week 4 Rapid Virological Response Predicts Sustained Response to Interferon-based Hepatitis C Treatment
9-03-2010

Pegylated Interferon plus Ribavirin Has High Sustained Response Rates in Children with Hepatitis C
8-31-2010

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Immune Cells Show Signs of Senescence after Liver Transplantation
7-09-2010

Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
7-05-2010

Blood-boosting Adjuvant Therapies Can Improve Response to Interferon-based Treatment for Hepatitis C
6-25-2010

Sustained Virological Response at 12 Weeks Post-treatment May be as Good as 24 Weeks for Determining Interferon Cure
6-11-2010

Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010

Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis
5-28-2010

HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
4-30-2010

Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
4-23-2010

Predictors of Rapid and Early Virological Response to Pegylated Interferon plus Ribavirin in Genotype 1 Hepatitis C Patients
4-9-2010

Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
2-12-2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1-12-2010

Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1-5-2010

Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
1-5-2010

HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients
12/04/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
11/17/09

Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12
10-16-2009

Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users
8-14-2009

Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study
7-28-2009

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09

Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09

Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/05/09

HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09

Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
4/07/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009

Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009

SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study
12/12/2008

Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders
12/08/2008

Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review
12/082008

Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008

Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008

Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008

Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin
11/21/2008

Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin
11/18/2008

IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008

Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008

IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
11/05/2008

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
11/05/2008

Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin
11/05/2008

Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study
11/05/2008

Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C
10/21/2008

Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals
10/17/08

24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response
10/14/08

Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
10/14/08

Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C
10/10/08

Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma
10/10/08

Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial
9/09/2008

Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin
8/29/2008



PegIntron + Rebetol
peginterferon alfa-2b + Rebetol (ribavirin)

PEG-INTRON® Prescribing Information
REBETOL® Prescribing Information

Articles on PegIntron + Rebetol

Week 4 Rapid Virological Response Predicts Sustained Response to Interferon-based Hepatitis C Treatment
9-03-2010

Pegylated Interferon plus Ribavirin Has High Sustained Response Rates in Children with Hepatitis C
8-31-2010

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Response at Week 8 Accurately Predicts Sustained Response to Pegylated Interferon plus Ribavirin for Hepatitis C
7-05-2010

Blood-boosting Adjuvant Therapies Can Improve Response to Interferon-based Treatment for Hepatitis C
6-25-2010

Sustained Virological Response at 12 Weeks Post-treatment May be as Good as 24 Weeks for Determining Interferon Cure
6-11-2010

Nitazoxanide Increases Response to Pegylated Interferon plus Ribavirin in Treatment-naive and Non-responder Hepatitis C Patients
5-28-2010

Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis
5-28-2010

Controlled Release Interferon (Locteron) Every 2 Weeks Works as Well as Pegylated Interferon but with Fewer Side Effects
5-18-2010

HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
4-30-2010

Closely Individualized Treatment with Pegylated Interferon plus Ribavirin Is Possible Based on Baseline Viral Load and Early Response
4-232010

Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
2-12-2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1-12-2010

Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1-5-2010

Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
1-5-2010

HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients
12/04/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09
Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
11/17/09

Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12
10-13-2009

Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users
8-14-2009

Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study
7-28-2009

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009

Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09

FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C
5/15/09

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09

Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis
5/05/09

Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients
5/05/09

Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09

Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/05/09

Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial) Final Analysis
5/05/09

Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study)
5/05/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
5/05/09

HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09

Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/2009

FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009

FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment
3/13/2009

Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
 2/03/2009

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009

Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009

PegIntron plus Ribavirin Approved for Children with Chronic Hepatitis C
1/05/2009

Intron A + Rebetol - (interferon alfa-2b + ribavirin)

Articles on Intron A + Rebetol

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

HCV Therapeutic Vaccine GI-5005 Improves Rate of Sustained Response to Interferon-based Therapy for Hepatitis C
4-30-2010

Interferon-based Therapy Less Effective for Hepatitis C Patients with Advanced Liver Fibrosis or Cirrhosis
4-9-2010

Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
2/16/2010

Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
1/29/2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1/12/2010

Sustained Response to Interferon-based Therapy Leads to Improved Quality of Life in Chronic Hepatitis C Patients
12/11/09

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients
11/24/09

HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Genetic Variation Helps Explain Differences in Response to Interferon-based Therapy for Hepatitis C
8-21-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009

Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009

Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
6-5-2009

HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans
6-2-2009

Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09

Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C
2/10/2009

CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C
12/05/2008

Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients
11/21/2008

Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C
11/14/2008

Roferon A + Ribavirin - (interferon alfa-2a + ribavirin)

Articles on Intron A + Rebetol

Asian Patients Respond as Well as Whites to Interferon-based Therapy for Chronic Hepatitis C
7-13-2010

Interferon-based Therapy Less Effective for Hepatitis C Patients with Advanced Liver Fibrosis or Cirrhosis
4-9-2010

Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
2/16/2010

Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
1/29/2010

Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy
1/12/2010

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients
11/24/09

HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009

Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009

Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09

Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Google Custom Search

Hepatitis C Main Section

FDA-approved Combination Therapies for Chronic HCV Infection
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Treatment Guidelines
Experimental Treatments
HCV Articles by Topic

Cirrhosis
Fibrosis
Hepatocellular Carcinoma
 Liver Transplantation
Liver Biopsy
Steatosis
 Anemia
Chilren / Infants / Women
Drug Abuse
 Experimental Treatments
 FAQs About Hepatitis C
 Genotypes
Insulin Resistance / Diabetes
Sustained Viral Response (SVR)
Tests for HCV
Vaccines for HCV